Market Research Logo

Low Back Pain - Pipeline Review, H1 2018

Low Back Pain - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H1 2018, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.

Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 10, 5, 4, 1 and 1 respectively.

Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Low Back Pain - Overview
Low Back Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Low Back Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Low Back Pain - Companies Involved in Therapeutics Development
Ache Laboratorios Farmaceuticos SA
Adynxx Inc
AnGes Inc
Array BioPharma Inc
Axsome Therapeutics Inc
Boehringer Ingelheim GmbH
Daewon Pharm Co Ltd
Egalet Corp
Frontier Biotechnologies Inc
Gador SA
Grunenthal GmbH
Hisamitsu Pharmaceutical Co Inc
Immune Pharmaceuticals Inc
Indena SpA
Inspyr Therapeutics Inc
MD Biosciences GmbH
Mesoblast Ltd
Nektar Therapeutics
Orion Corporation
Pacira Pharmaceuticals Inc
Pfizer Inc
Stayble Therapeutics AB
Therapix Biosciences Ltd
Low Back Pain - Drug Profiles
(acetaminophen + caffeine + diclofenac sodium + orphenadrine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(clonidine + naltrexone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diclofenac epolamine + lidocaine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(eperisone + pelubiprofen) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(loxoprofen + methocarbamol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aceclofenac + eperisone SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARRY-954 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AYX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bupivacaine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cebranopadol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexmedetomidine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol + palmidrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HP-3150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDN-5243 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IG-8801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MD-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPC-06ID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxycodone hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize ADORA2A for Low Back Pain, Arthritis Pain and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STA-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STA-363 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zoledronate disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Low Back Pain - Dormant Projects
Low Back Pain - Discontinued Products
Low Back Pain - Product Development Milestones
Featured News & Press Releases
Mar 29, 2018: Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment
Mar 20, 2018: Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain
Feb 27, 2018: AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain
Feb 20, 2018: Egalet Announces Issuance of New U.S. Patent for Guardian Technology
Nov 28, 2017: Egalet Announces Positive Top-Line Results from Phase 3 Study Evaluating Efficacy and Safety of Egalet-002 in Patients with Moderate-to-Severe Chronic Low Back Pain
Sep 25, 2017: Mesoblast Provides Update on lead product candidate MPC-06-ID at Global Healthcare Conferences
Jun 13, 2017: Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab
Apr 25, 2017: AnGes Announces FDA Clearance of Investigational New Drug Application for NF-kappaB decoy oligo DNA to treat discogenic lower back pain
Mar 24, 2017: AnGes: Investigational New Drug (IND) Application Submitted to the FDA
Mar 20, 2017: NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain
Mar 15, 2017: Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast’s Cell Therapy
Aug 01, 2016: MesoblastS Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science
Jul 25, 2016: Hisamitsu Pharmaceutical Announces the results of Phase II clinical study of HP-3150 in Japan for “Lower back pain” (an analgesic transdermal drug containing NSAIDs)
Jun 22, 2016: Frontier Biotech Reports Primary Endpoint Met in Phase 2 Trial of AB001 In Chronic Low Back Pain
Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Low Back Pain, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Low Back Pain - Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2018
Low Back Pain - Pipeline by Adynxx Inc, H1 2018
Low Back Pain - Pipeline by AnGes Inc, H1 2018
Low Back Pain - Pipeline by Array BioPharma Inc, H1 2018
Low Back Pain - Pipeline by Axsome Therapeutics Inc, H1 2018
Low Back Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Low Back Pain - Pipeline by Daewon Pharm Co Ltd, H1 2018
Low Back Pain - Pipeline by Egalet Corp, H1 2018
Low Back Pain - Pipeline by Frontier Biotechnologies Inc, H1 2018
Low Back Pain - Pipeline by Gador SA, H1 2018
Low Back Pain - Pipeline by Grunenthal GmbH, H1 2018
Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2018
Low Back Pain - Pipeline by Immune Pharmaceuticals Inc, H1 2018
Low Back Pain - Pipeline by Indena SpA, H1 2018
Low Back Pain - Pipeline by Inspyr Therapeutics Inc, H1 2018
Low Back Pain - Pipeline by MD Biosciences GmbH, H1 2018
Low Back Pain - Pipeline by Mesoblast Ltd, H1 2018
Low Back Pain - Pipeline by Nektar Therapeutics, H1 2018
Low Back Pain - Pipeline by Orion Corporation, H1 2018
Low Back Pain - Pipeline by Pacira Pharmaceuticals Inc, H1 2018
Low Back Pain - Pipeline by Pfizer Inc, H1 2018
Low Back Pain - Pipeline by Stayble Therapeutics AB, H1 2018
Low Back Pain - Pipeline by Therapix Biosciences Ltd, H1 2018
Low Back Pain - Dormant Projects, H1 2018
Low Back Pain - Dormant Projects, H1 2018 (Contd..1), H1 2018
Low Back Pain - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Low Back Pain, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report